OVARIAN MUCINOUS CYSTADENOCARCINOMA
Clinical trials for OVARIAN MUCINOUS CYSTADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new OVARIAN MUCINOUS CYSTADENOCARCINOMA trials appear
Sign up with your email to follow new studies for OVARIAN MUCINOUS CYSTADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Scientists test Two-Drug attack on tough brain and solid tumors
Disease control OngoingThis early-stage study is testing the safety and best dose of a new oral drug, MLN0128, when given with the existing cancer drug bevacizumab. It is for adults with recurrent glioblastoma (a type of brain tumor) or other advanced solid tumors that have stopped responding to standa…
Matched conditions: OVARIAN MUCINOUS CYSTADENOCARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:28 UTC
-
Major cancer trial tests new drug combo for Tough-to-Treat ovarian cancer
Disease control OngoingThis large, late-stage trial is testing which combination of chemotherapy drugs works best for women with a specific type of ovarian or fallopian tube cancer (mucinous adenocarcinoma). It compares two standard drug pairs, with or without an added drug (bevacizumab) that blocks tu…
Matched conditions: OVARIAN MUCINOUS CYSTADENOCARCINOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 24, 2026 12:02 UTC
-
New hope for Tough-to-Treat ovarian cancers?
Disease control OngoingThis study is testing if adding an experimental drug called AZD1775 to a standard chemotherapy (gemcitabine) works better than the chemotherapy alone. It is for women whose ovarian, fallopian tube, or primary peritoneal cancer has returned and stopped responding to platinum-based…
Matched conditions: OVARIAN MUCINOUS CYSTADENOCARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 20, 2026 14:47 UTC